Researchers Identify Causes and Mechanisms of Polycystic Ovary Syndrome Using Family-Based Genetic Analysis
The findings will enable personalized medicine approaches to disease prediction and potential new therapies for PCOS
A first-of-its-kind study using family-based genetic analysis has confirmed a gene involved in male hormone production, DENND1A, plays a major role in the development of polycystic ovary syndrome (PCOS). The discovery will enable personalized medicine approaches to PCOS, including better disease prediction. The findings are available online in The Journal of Clinical Endocrinology & Metabolism.
PCOS is among the most common endocrine conditions in reproductive-age women and is the leading cause of infertility and type 2 diabetes. The cause of PCOS is unknown, but there is a strong inherited susceptibility to the disorder. A number of common PCOS genetic variants that slightly increase disease risk have been mapped in previous genome-wide association studies, however the genes found to date account for only a small amount of PCOS disease risk.
“PCOS is a major cause of female infertility and is associated with other serious health problems,” said one of the senior authors of the study, Andrea Dunaif, MD, Chief of the Hilda and J. Lester Gabrilove Division of Endocrinology, Diabetes and Bone Disease at the Icahn School of Medicine at Mount Sinai. “Our findings provide important new insights into the mechanisms by which genetic variation causes PCOS. The rare genetic variants we found may be much better for predicting the condition than the common variants. Further, targeting pathways regulated by this gene could lead to new therapies for the condition.”
In the study, the researchers explored the genetic basis of PCOS by conducting whole-genome sequencing on DNA from the members of 62 families of women with PCOS. These families included both parents and one or more reproductive-age daughters with PCOS as well as unaffected daughters. Bioinformatic analyses were performed to determine which genes contained variants that were likely to be damaging. Only genes that were inherited from a parent were included for further analysis.
Dr. Dunaif and her colleagues found that reproductive and metabolic hormone levels were associated with rare genetic variants in DENND1A in approximately half of the families. This gene is important in testosterone production in the ovary; increased ovarian testosterone production is a major hormonal abnormality in PCOS. The findings indicate that this type of genetic variation contributes to the distinctive hormonal profile of the disorder.
The research was begun by Dr. Dunaif and colleagues at Northwestern University Feinberg School of Medicine and completed at the Icahn School of Medicine Mount Sinai.
“After sequencing the entire genomes of many families affected by the disease, we can determine how certain rare genetic variants are associated with PCOS,” said Geoffrey Hayes, PhD, Associate Professor in the Department of Medicine – Endocrinology, Metabolism and Molecular Medicine at Northwestern University Feinberg School of Medicine, and co-senior author of this study. “We hope our results will help uncover some of the involved hereditary mechanisms and ultimately teach us more about the molecular drivers of the disorder. This approach should be applicable to other common complex diseases affecting humans including diabetes and heart disease.”
Matthew Dapas, PhD Candidate in the Department of Medicine at Northwestern University Feinberg School of Medicine, was the first author on the study and integral to this research.
This research was funded by the U.S. National Institutes of Health.
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.